Posted by Michael Wonder on 15 Dec 2020
Over-the-counter access to low dose cannabidiol
15 December 2020 - Today the Therapeutic Goods Administration announced a final decision to down-schedule certain low dose cannabidiol preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine).
The decision will allow low-dose cannabidiol containing products, up to a maximum of 150 mg/day, for use in adults that have been approved by the TGA, to be supplied over-the-counter by a pharmacist, without a prescription.
The decision limits over-the-counter supply to only those products that are approved by the TGA and included on the Australian Register of Therapeutic Goods. The decision also outlines additional limits on dosage form and packaging requirements, including pack size and child resistant closures.
